Genmab — Maj 2018
-
EMA:
The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs) for the following medicines:
• Daratumumab, EMEA-002152-PIP01-17, from Janssen-Cilag International N.V., for the treatment of lymphoid malignancies (except mature B-cell neoplasms); http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2018/05/WC500248882.pdf -
Recommendations for submission of supplementary information for Dara, signal Encephalopathy, to Assess in the next PSUR (submission by 24 July 2018) - http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation_on_signal/2018/04/WC500247424.pdf p8
-
another Tecentriq disappointment in colorectal cancer https://www.reuters.com/article/us-roche-immunotherapy/setback-to-roche-hopes-for-tecentriq-as-fails-key-cancer-trial-idUSKBN1IB16N
-
God morgen.
-
God morgen
-
interesting interview on the MASTER trial - https://myelomacrowd.org/full-show-master-trial/
-
-
Danke vel
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind